Translatability of In Vitro Stress for Predicting Deamidation and Oxidation Biotransformation on Biotherapeutics.
Autor: | Chu PY; Genentech, South San Francisco, California 94080-4990, United States., Wang H; NovaBioAssays, Woburn, Massachusetts, 01801, United States., Ross E; Genentech, South San Francisco, California 94080-4990, United States., Stephens N; Genentech, South San Francisco, California 94080-4990, United States., Zhang HM; Genentech, South San Francisco, California 94080-4990, United States., Andersen N; Genentech, South San Francisco, California 94080-4990, United States., Chan W; Genentech, South San Francisco, California 94080-4990, United States., Shivva V; Genentech, South San Francisco, California 94080-4990, United States., Crowell SR; Genentech, South San Francisco, California 94080-4990, United States., Spiess C; Genentech, South San Francisco, California 94080-4990, United States., Holder PG; Genentech, South San Francisco, California 94080-4990, United States., Agard NJ; Genentech, South San Francisco, California 94080-4990, United States., Ji C; NovaBioAssays, Woburn, Massachusetts, 01801, United States., Chen J; NovaBioAssays, Woburn, Massachusetts, 01801, United States., Sreedhara A; Genentech, South San Francisco, California 94080-4990, United States., Wang J; Genentech, South San Francisco, California 94080-4990, United States., Wu C; Genentech, South San Francisco, California 94080-4990, United States., Liu Y; Genentech, South San Francisco, California 94080-4990, United States., Tran JC; Genentech, South San Francisco, California 94080-4990, United States. |
---|---|
Jazyk: | angličtina |
Zdroj: | Analytical chemistry [Anal Chem] 2023 Dec 12; Vol. 95 (49), pp. 17957-17961. Date of Electronic Publication: 2023 Nov 30. |
DOI: | 10.1021/acs.analchem.3c02133 |
Abstrakt: | Biotransformation leading to single residue modifications (e.g., deamidation, oxidation) can contribute to decreased efficacy/potency, poor pharmacokinetics, and/or toxicity/immunogenicity for protein therapeutics. Identifying and characterizing such liabilities in vivo are emerging needs for biologics drug discovery. In vitro stress assays involving PBS for deamidation or AAPH for oxidation are commonly used for predicting liabilities in manufacturing and storage and are sometimes considered a predictive tool for in vivo liabilities. However, reports discussing their in vivo translatability are limited. Herein, we introduce a mass spectrometry workflow that characterizes in vivo oxidation and deamidation in pharmacokinetically relevant compartments for diverse protein therapeutic modalities. The workflow has low bias of <10% in quantitating degradation in the relevant pharmacokinetic concentration range for monkey and rabbit serum/plasma (1-100 μg/mL) and allows for high sequence coverage (∼85%) for discovery/monitoring of amino acid modifications. For oxidation and deamidation, the assay was precise, with percent coefficient of variation of <8% at 1-100 μg/mL and ≤6% method-induced artifacts. A high degree of in vitro and in vivo correlation was observed for deamidation on the six diverse protein therapeutics (seven liability sites) tested. In vivo translatability for oxidation liabilities were not observed for the 11 molecules tested using in vitro AAPH stress. One of the molecules dosed in eyes resulted in a false positive and a false negative prediction for in vivo oxidation following AAPH stress. Finally, peroxide stress was also tested but resulted in limited success (1 out of 4 molecules) in predicting oxidation liabilities. |
Databáze: | MEDLINE |
Externí odkaz: |